As bank investors, it's easy to get focused on the big banks. They make a lot of noise and are regularly in the news: more than occasionally for the wrong reasons. But we focus on the giants and ignore the regionals at our own investing peril.
The best regional banks can take serious financial power and investment finesse and turn it into share-price appreciation without the annoying drama and potentially dangerous hubris of the too-big-to-fail institutions. PNC Financial (NYSE: PNC ) is one of these low-drama, high-power banks. Here are three reasons to buy stock in this Pittsburgh-based powerhouse right now.
1. Big-bank beating first-quarter earnings
For the first quarter of 2013, PNC reported net income of $1.0 billion. For the first quarter of 2012, PNC's net income was $811 million. That makes for an increase of 23.3%. Wells Fargo (NYSE: WFC ) came close to but couldn't quite match PNC's performance, with net-income growth of 22% year over year. �
Top 5 Income Companies To Buy Right Now: Pendrell Corp (PCO)
Pendrell Corporation (Pendrell), formerly ICO Global Communications (Holdings) Limited, incorporated on March 17, 2000, is a fully-integrated intellectual property (IP) investment and advisory company. The Company develops and implements strategies to create, acquire, commercialize and license IP. The Company provides IP valuation services, analysis and strategic advice through Pendrell�� wholly owned subsidiary, Pendrell Technologies LLC (PTL) and its wholly owned subsidiary, Ovidian Group LLC (Ovidian Group). It also assists its clients with a rangeof IP services, including IP valuation and investment analysis, IP landscape analysis, IP divestitures and IP risk mitigation strategies. On June 17, 2011, the Company acquired Ovidian Group. On October 31, 2011, the Company�� subsidiary, Pendrell Technologies LLC, acquired 90.1% interest in ContentGuard Holdings, Inc. In November 2011, Technicolor SA sold its 25.7% interest in ContentGuard to Pendrell Technologies LLC, a wholly owned subsidiary of Pendrell Corporation. During the year ended December 31, 2011, the Company completed the divestiture of its satellite communications assets. Effective February 25, 2013, the Company acquired 68% interest in Provitro Biosciences LLC.
The Company competes with Acacia Research Corporation, Coller IP Management, Intellectual Ventures, Mosaid, Rovi, RPX, Wi-Lan, Boston Consulting Group, Bain & Company and Red Chalk Group.
Advisors' Opinion:- [By Roberto Pedone]
Pendrell (PCO) is a fully integrated intellectual property investment and advisory firm. This stock closed up 2.3% to $2.18 in Tuesday's trading session.
Tuesday's Range: $2.08-$2.22
52-Week Range: $1.04-$2.71
Tuesday's Volume: 263,000
Three-Month Average Volume: 457,962From a technical perspective, PCO bounced higher here back above its 50-day moving average of $2.16 with lighter-than-average volume. This move is quickly pushing shares of PCO within range of triggering a near-term breakout trade. That trade will hit if PCO manages to take out some near-term overhead resistance at $2.22 with high volume.
Traders should now look for long-biased trades in PCO as long as it's trending above Tuesday's low of $2.08 or above $2 and then once it sustains a move or close above $2.22 with volume that hits near or above 457,962 shares. If that breakout triggers soon, then PCO will set up to re-test or possibly take out its next major overhead resistance levels at $2.50 to its 52-week high at $2.71.
Top 5 Income Companies To Buy Right Now: Sun Hydraulics Corp (SNHY)
Sun Hydraulics Corporation (Sun) designs, manufactures, and sells screw-in cartridge valves and manifolds used in hydraulic systems. The Company has facilities in the United States, the United Kingdom, Germany, Korea, France, and China. Sun Hydraulik Holdings Limited (Sun Holdings), a wholly owned subsidiary of Sun was formed to provide a holding company for the European market operations; its wholly owned subsidiaries are Sun Hydraulics Limited (Sun Ltd.) and Sun Hydraulik GmbH (Sun GmbH). Sun Ltd. operates a manufacturing and distribution facility located in Coventry, England, and Sun GmbH operates a manufacturing and distribution facility located in Erkelenz, Germany. Sun Hydraulics Korea Corporation (Sun Korea), a wholly owned subsidiary of Sun, operates a manufacturing and distribution facility. Sun Hydraulics, SARL (Sun France), a wholly owned subsidiary of Sun was dissolved in November 2011. Sun Hydraulics (India) a liaison office in Bangalore, India is used to develop new business opportunities in the Indian market. WhiteOak Controls, Inc. (WhiteOak), a 40% equity method investment, located in Mediapolis, Iowa, designs and produces complementary electronic control products. On September 27, 2011, Sun acquired High Country Tek, Inc. (HCT), which designs and manufactures a range of standard and customizable electronic control modules used to interpret electronic signals.
Screw-in Hydraulic Cartridge Valves
The Company�� screw-in hydraulic cartridge valves are offered in five size ranges and include both electrically actuated and non-electrically actuated products. The floating construction introduced by the Company results in a self alignment characteristic.
Standard Manifolds
A manifold is a solid block of metal, usually aluminum or ductile iron, which is machined to create threaded cavities and channels into which screw-in cartridge valves can be installed and through which the hydraulic fluid flows. The Company�� range of standard mani! folds enables the customers to integrate its screw-in cartridge valves into their machinery and equipment.
Integrated Packages
An integrated package consists of multiple cartridges assembled into a custom designed manifold for a specific customer to provide the specific operating characteristics of a customer�� circuit. The Company�� screw-in cartridge valves translate to integrated packages designed by the Company and result in products that are smaller in size. Due to the self-alignment characteristic, the Company�� integrated packages do not require testing once assembled.
Electronic Controllers
HCT designs and manufactures electronic controllers, which manage the function of electrically actuated valves. HCT�� products range from one valve, manually adjusted controllers to fully integrated hydraulic control systems managing multiple hydraulic valves, as well as other input and output products, such as joysticks and displays.
Advisors' Opinion:- [By Sally Jones]
Sun Hydraulics Corp. (SNHY): Reduced
Up 25% over 12 months, Sun Hydraulics Corp. has a market cap of $787.4 million; its shares were traded at around $30.00 with a P/E ratio of 21.20.
Top 5 Paper Companies To Buy For 2015: RLJ Lodging Trust(RLJ)
RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States. The firm primarily invests in premium-branded, focused service, and compact full-service hotels. RLJ Lodging Trust was launched in 2000 and is domiciled in Bethesda, Maryland.
Advisors' Opinion:- [By Markus Aarnio]
American Hotel Income Properties' competitors include Hospitality Properties Trust (HPT), RLJ Lodging Trust (RLJ), and Hersha Hospitality Trust (HT).
Top 5 Income Companies To Buy Right Now: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By Ben Levisohn]
Shares of Gilead (GILD) and Celgene (CELG) have tumbled today after both companies revealed that they were facing patent pressures.
For Gilead, Idenix Pharmaceuticals (IDIX) filed a patent-infringement lawsuit that appears to target Gilead’s Sovaldi (someone please correct me if I’m wrong). For Celgene, it was the decision of a New Jersey court to schedule a hearing on a patent case for April 29, earlier than expected. It hasn’t helped that the UK’s National Institute for Health and Care Excellence also said that Celgene’s Revlimid doesn’t work well enough to be covered for “second line treatment of multiple myeloma.”
Top 5 Income Companies To Buy Right Now: Sibling Group Holdings Inc (SIBE)
Sibling Group Holdings Inc., incorporated on December 28, 1988, is a development-stage company. During the year ended December 31, 2012, the Company was not engaged in any business operations.
The Company has entered into an Agreement of Acquisition and Plan of Reorganization with Sibling Entertainment Group, Inc. (Sibling) to acquire Sibling�� four wholly owned subsidiaries: Sibling Theatricals, Inc., Sibling Pictures, Inc., Sibling Music Corp., and Sibling Properties, Inc. and their subsidiaries, including Dick Foster Productions, Inc., Adrenaline MMA, Inc., Hats Holdings, Inc. amongst others. The Company was organized primarily for the purpose of importing fruits and vegetables from Latin America.
Advisors' Opinion:- [By Peter Graham]
Small cap holding companies Sibling Group Holdings Inc (OTCMKTS: SIBE), Tranzbyte Corp (OTCMKTS: ERBB) and Readen Holding Corp (OTCMKTS: RHCO) are in the business of holding or acquiring other companies. They have also been getting some attention lately in various investment newsletters and not necessarily because of acquisitions or other news but rather because of a few recent paid promotions. With that in mind, here is a quick look and a reality check about all three:
Sibling Group Holdings Inc (OTCMKTS: SIBE) Has Been Quiet LatelySmall cap Sibling Group Holdings intends to acquire, on a global basis, advanced technology and education management operations in order to enhance and accelerate the delivery of 21st century learning. On Friday, Sibling Group Holdings closed at $0.05 for a market cap of $39,342 plus SIBE is down 96.7% over the past year and down 80% over the past five years according to Google Finance.
No comments:
Post a Comment